InspireMDSTU:II2 42 9-Day RSI is 33.54 as of Jul. 03, 2026. GuruFocus rates STU:II2 with a GF Score™ of 42/100 and a GF Value™ of €1.48 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 870 Medical Devices & Instruments companies, InspireMD ranks better than 75.06% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-03), InspireMD's 9-Day RSI is 33.54.
The industry rank for InspireMD's 9-Day RSI or its related term are showing as below:
STU:II2's 9-Day RSI is ranked better than 75.06% of 870
companies
in the Medical Devices & Instruments industry
Industry Median: 49.14
vs STU:II2: 33.54
InspireMD (STU:II2) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
InspireMD 9-Day RSI Related Terms
STU:II2 vs TELA, BDMD, PAVM: 9-Day RSI Comparison
For the Medical Devices subindustry, InspireMD's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InspireMD 9-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, InspireMD's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where InspireMD's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InspireMD (STU:II2) has a 9-Day RSI of 33.54 as of Jul. 03, 2026. According to the industry distribution chart, InspireMD ranks #217 out of 870 companies in the Medical Devices & Instruments industry, placing it in the top 24.9%.
Is InspireMD's 9-Day RSI too high?
InspireMD's current 9-Day RSI is 33.54. The Medical Devices & Instruments industry median 9-Day RSI is 49.14. InspireMD's value of 33.54 is 31.7% below this industry median. Based on the distribution chart, InspireMD ranks #217 out of 870 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, InspireMD has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InspireMD's 9-Day RSI compare to TELA and BDMD?
According to the Medical Devices & Instruments industry distribution chart, InspireMD ranks #217 out of 870 companies for 9-Day RSI. This places InspireMD in the top 25% of its industry — outperforming the majority of peers. The industry median 9-Day RSI is 49.14. InspireMD's value of 33.54 is 31.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Medical Devices & Instruments company?
The median 9-Day RSI among Medical Devices & Instruments companies is 49.14, based on 870 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InspireMD's current 9-Day RSI of 33.54 is 31.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median 9-Day RSI is 49.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InspireMD's current 9-Day RSI is 33.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InspireMD stock overvalued right now?
Based on GuruFocus' analysis, InspireMD (STU:II2) is currently considered Possible Value Trap. The stock's GF Value™ is €1.48, compared to a current price of €0.59 — trading 60.5% below its estimated fair value. The current 9-Day RSI is 33.54 and 31.7% below the Medical Devices & Instruments industry median of 49.14. InspireMD's overall GF Score™ is 42/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For InspireMD (STU:II2), the current 9-Day RSI is 33.54 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InspireMD (STU:II2) Overvalued in 2026?
Based on GuruFocus' analysis, InspireMD stock appears to be undervalued.
The current stock price of €0.59 is trading 60.5% below its estimated GF Value™ of €1.48.
GuruFocus considers InspireMD to be Possible Value Trap.
Key valuation signals for STU:II2:
9-Day RSI: 33.54
GF Value™: €1.48 vs. price of €0.59 (60.5% below fair value)
Industry Position: 31.7% below the Medical Devices & Instruments median (#217 of 870)
No single metric tells the full story. See the STU:II2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.
42GF Score
Get the complete analysis for STU:II2
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:II2 has been successfully added to your 